Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CEL SCI CORPCVM · Entity 7495 | Director | August 14, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CEL SCI CORP
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.49 · Expires 2036-08-13 | Direct | 137,271 |
Reported balance
After 2026-08-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 110,000 · Balance 137,271 F1: The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in three (3) equal annual installments commencing one year after the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 13:43 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 110,000 | $0.01 Strike: $1.49 | $1,100.00 |
DisclosureSEC source: 0001511858-26-000001 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,271 Underlying: Common Stock · 110,000 shares Expires 2036-08-13 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 21:20 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 4,000 | $0.01 Strike: $8.20 | $40.00 |
DisclosureSEC source: 0001236030-25-000014 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,266 Underlying: Common Stock · 4,000 shares Expires 2035-07-27 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 11:56 UTC | CEL SCI CORP CVM · Entity 7495 | PurchaseCommon Stock | 2,919 | $6.85 | $19,995.15 |
DisclosureSEC source: 0001236030-25-000008 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,733 F1 · shares: On July 25, 2025, Mr. Watson purchased 2,919 shares of restricted stock directly from the Company at the closing price on July 24, 2025, the most recent closing price available. Read SEC document |
| May 08, 2024 Filed May 10, 2024 13:04 UTC | CEL SCI CORP CVM · Entity 7495 | PurchaseCommon Stock | 20,000 | $1.39 | $27,800.00 |
DisclosureSEC source: 0001236030-24-000015 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,431 F1 · shares: On May 8, 2024, Mr. Watson purchased 20,000 shares of restricted stock directly from the Company at the closing price on May 8, 2024, the most recent closing price available. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 21:23 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 64,000 | $0.01 Strike: $1.50 | $640.00 |
DisclosureSEC source: 0001236030-24-000011 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 698,000 Underlying: Common Stock · 64,000 shares Expires 2034-04-18 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:50 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 64,000 | $0.01 Strike: $1.36 | $640.00 |
DisclosureSEC source: 0001236030-23-000013 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634,000 Underlying: Common Stock · 64,000 shares Expires 2033-08-07 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 21:30 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 64,000 | $0.01 Strike: $3.35 | $640.00 |
DisclosureSEC source: 0001236030-22-000016 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,000 Underlying: Common Stock · 64,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 14:51 UTC | CEL SCI CORP CVM · Entity 7495 | PurchaseCommon Stock | 1,250 | $8.00 | $10,000.00 |
DisclosureSEC source: 0001646989-21-000008 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,431 Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:34 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 128,000 | $0.01 Strike: $20.61 | $1,280.00 |
DisclosureSEC source: 0001236215-21-000010 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,000 Underlying: Common Stock · 128,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 14:59 UTC | CEL SCI CORP CVM · Entity 7495 | PurchaseCommon Stock | 800 | $11.77 | $9,416.00 |
DisclosureSEC source: 0001236031-20-000034 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,181 Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 21:05 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 128,000 | $0.01 Strike: $10.93 | $1,280.00 |
DisclosureSEC source: 0001236031-20-000023 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,000 Underlying: Common Stock · 128,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 12:57 UTC | CEL SCI CORP CVM · Entity 7495 | PurchaseCommon Stock | 923 | $10.83 | $9,996.09 |
DisclosureSEC source: 0001236031-20-000011 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,381 F1 · shares: On February 26, 2020, Mr. Watson purchased $10,000 worth of restricted stock directly from the Company at the closing price on February 26, 2020, the most recent closing price available. Read SEC document |
| May 07, 2019 Filed May 8, 2019 12:12 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 1,458 | $6.86 | $10,001.88 |
DisclosureSEC source: 0001236031-19-000019 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458 Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:03 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 160,000 | $0.01 Strike: $5.65 | $1,600.00 |
DisclosureSEC source: 0001236031-19-000014 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 160,000 shares Expires 2029-04-10 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:59 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 80,000 | $0.01 Strike: $2.45 | $800.00 |
DisclosureSEC source: 0001236031-18-000023 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 80,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| December 18, 2017 Filed Jan 16, 2018 21:28 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 10,000 | $0.01 Strike: $1.84 | $100.00 |
DisclosureSEC source: 0001236031-18-000006 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-12-17 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.